Publicacións (371) Publicacións de Juan Jesús Gómez-Reino Carnota

2023

  1. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: Results from the open-label, randomised controlled ORAL Surveillance trial

    Annals of the Rheumatic Diseases, Vol. 82, Núm. 3, pp. 331-343

2022

  1. After JAK inhibitor failure: To cycle or to switch, that is the question - Data from the JAK-pot collaboration of registries

    Annals of the Rheumatic Diseases, Vol. 82, Núm. 2, pp. 175-181

  2. Biologics for thyroid eye disease

    Foundational Papers in Oculoplastics (Springer International Publishing), pp. 481-498

  3. Inmune-mediated inflammatory rheumatic diseases in transgender people: A scoping review

    Seminars in Arthritis and Rheumatism, Vol. 52

2021

  1. Adherence to treatment in patients with rheumatoid arthritis from spain

    Patient Preference and Adherence, Vol. 15, pp. 111-117

  2. Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial

    Rheumatology (United Kingdom), Vol. 60, Núm. 1, pp. 256-262

  3. Update of the Position Paper of the Spanish Society of Rheumatology on Biosimilar Drugs

    Reumatologia Clinica, Vol. 17, Núm. 3, pp. 160-169

2020

  1. Chemical exposure-induced systemic fibrosing disorders: Novel insights into systemic sclerosis etiology and pathogenesis

    Seminars in Arthritis and Rheumatism, Vol. 50, Núm. 6, pp. 1226-1237

  2. Influence of age on the occurrence of adverse events in rheumatic patients at the onset of biological treatment: Data from the BIOBADASER III register

    Arthritis Research and Therapy, Vol. 22, Núm. 1

  3. Long-Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials

    ACR Open Rheumatology, Vol. 2, Núm. 8, pp. 459-470

  4. Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis

    Current Therapeutic Research - Clinical and Experimental, Vol. 93

  5. Risk/benefit management in the infectious phase in systemic autoimmune rheumatic diseases

    Handbook of Systemic Autoimmune Diseases (Elsevier Ltd), pp. 179-203

  6. Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies

    ACR Open Rheumatology, Vol. 2, Núm. 10, pp. 543-554

2019

  1. Abatacept for the treatment of rheumatoid arthritis

    Expert Review of Clinical Immunology, Vol. 15, Núm. 4, pp. 319-326

  2. Changing rate of serious infections in biologic-exposed rheumatoid arthritis patients. Data from South American registries BIOBADABRASIL and BIOBADASAR

    Clinical Rheumatology, Vol. 38, Núm. 8, pp. 2129-2139

  3. Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept

    PLoS ONE, Vol. 14, Núm. 2

  4. Factors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the Spanish BIOBADASER registry

    Rheumatology International, Vol. 39, Núm. 3, pp. 509-515

  5. Objectives and methodology of BIOBADASER phase III

    Reumatologia Clinica, Vol. 15, Núm. 4, pp. 229-236

  6. Specific Association of HLA–DRB1*03 With Anti–Carbamylated Protein Antibodies in Patients With Rheumatoid Arthritis

    Arthritis and Rheumatology, Vol. 71, Núm. 3, pp. 331-339

  7. The role of registries in the treatment of rheumatoid arthritis with biologic disease-modifying anti-rheumatic drugs

    Pharmacological Research, Vol. 148